344 related articles for article (PubMed ID: 29807823)
1. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
[TBL] [Abstract][Full Text] [Related]
2. [Neuromodulation as a treatment for overactive bladder syndrome].
Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
4. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie J; Wilson DI; Herbison GP; Wilson D
Cochrane Database Syst Rev; 2007 Jul; (3):CD005493. PubMed ID: 17636801
[TBL] [Abstract][Full Text] [Related]
6. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
7. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
[TBL] [Abstract][Full Text] [Related]
8. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
Timm B; Jayarajan J; Chan G; Bolton D
Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
[TBL] [Abstract][Full Text] [Related]
9. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
Rachaneni S; Latthe P
Int Urogynecol J; 2017 Jun; 28(6):805-816. PubMed ID: 28083714
[TBL] [Abstract][Full Text] [Related]
11. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
[TBL] [Abstract][Full Text] [Related]
12. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
13. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
14. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
15. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
Malde S; Fry C; Schurch B; Marcelissen T; Averbeck M; Digesu A; Sahai A
Neurourol Urodyn; 2018 Jun; 37(S4):S108-S116. PubMed ID: 30133790
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences for treating refractory overactive bladder in the UK.
Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
[TBL] [Abstract][Full Text] [Related]
17. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Ellsworth P
Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
[TBL] [Abstract][Full Text] [Related]
18. [Update on the second line management of idiopathic overactive bladder].
Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
[TBL] [Abstract][Full Text] [Related]
19. How can we better manage drug-resistant OAB/DO? ICI-RS 2018.
Chermansky C; Schurch B; Rahnama'i MS; Averbeck MA; Malde S; Mancini V; Valentini F; Sahai A
Neurourol Urodyn; 2019 Dec; 38 Suppl 5():S46-S55. PubMed ID: 31821628
[TBL] [Abstract][Full Text] [Related]
20. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
Sherif H; Khalil M; Omar R
Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
